919 related articles for article (PubMed ID: 16715941)
1. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
2. [Multicenter evaluation of a newly developed microdilution test, brothMIC NTM to determine minimum inhibitory concentrations of antimicrobial agents for nontuberculous mycobacteria].
Yamane N; Onaga S; Saitoh H; Toyoshima S; Shimojima M; Kawahara S; Takashima T; Yamashita T
Rinsho Byori; 2002 Apr; 50(4):381-91. PubMed ID: 12014018
[TBL] [Abstract][Full Text] [Related]
3. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
5. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
Hombach M; Somoskövi A; Hömke R; Ritter C; Böttger EC
Int J Med Microbiol; 2013 Jul; 303(5):270-6. PubMed ID: 23689069
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
[TBL] [Abstract][Full Text] [Related]
8. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
9. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
10. [Non-tuberculous mycobacteriosis. What has been coming out].
Kajiki A
Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
[TBL] [Abstract][Full Text] [Related]
11. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clarithromycin-sensitive and clarithromycin-resistant Mycobacterium avium strains isolated from AIDS patients during therapy regimens including clarithromycin.
Matsiota-Bernard P; Zinzendorf N; Onody C; Guenounou M
J Infect; 2000 Jan; 40(1):49-54. PubMed ID: 10762111
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
Cai S; Sato K; Shimizu T; Yamabe S; Hiraki M; Sano C; Tomioka H
J Antimicrob Chemother; 2006 Jan; 57(1):85-93. PubMed ID: 16303883
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
Tsukamura M
Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
[TBL] [Abstract][Full Text] [Related]
16. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
Kawahara S; Nagare H
Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
[TBL] [Abstract][Full Text] [Related]
17. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.
Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C
Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316
[TBL] [Abstract][Full Text] [Related]
18. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008.
Wang HX; Yue J; Han M; Yang JH; Gao RL; Jing LJ; Yang SS; Zhao YL
Chin Med J (Engl); 2010 Jan; 123(2):184-7. PubMed ID: 20137367
[TBL] [Abstract][Full Text] [Related]
19. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
20. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Bhusal Y; Shiohira CM; Yamane N
Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]